Ident. | Authors (with country if any) | Title |
---|
000107 (2011) |
Karl Kieburtz [États-Unis] | Twice‐daily, low‐dose pramipexole in early Parkinson's disease: A randomized, placebo‐controlled trial |
000112 (2011) |
Gabriella Constantinescu [Australie] ; Deborah Theodoros [Australie] ; Trevor Russell [Australie] ; Elizabeth Ward [Australie] ; Stephen Wilson [Australie] ; Richard Wootton [Royaume-Uni] | Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non‐inferiority trial |
000113 (2011) |
István Sziklai [Hongrie] ; Judit Szilvássy [Hongrie] ; Zoltán Szilvássy [Hongrie] | Tinnitus control by dopamine agonist pramipexole in presbycusis patients: A randomized, placebo‐controlled, double‐blind study |
000127 (2011) |
Hasmet A. Hanagasi [Turquie] ; Hakan Gurvit [Turquie] ; P Nar Unsalan [Turquie] ; Hilal Horozoglu [Turquie] ; Nese Tuncer [Turquie] ; Aynur Feyzioglu [Turquie] ; Dilek Ince Gunal [Turquie] ; Gorsev G. Yener [Turquie] ; Raif Cakmur [Turquie] ; Huseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study |
000164 (2011) |
Claudia Trenkwalder [Allemagne] ; Bryan Kies [Afrique du Sud] ; Monika Rudzinska [Pologne] ; Jennifer Fine [Afrique du Sud] ; Janos Nikl [Hongrie] ; Krystyna Honczarenko [Pologne] ; Peter Dioszeghy [Hongrie] ; Dennis Hill [États-Unis] ; Tim Anderson [Nouvelle-Zélande] ; Vilho Myllyla [Finlande] ; Jan Kassubek [Allemagne] ; Malcolm Steiger [Royaume-Uni] ; Marco Zucconi [Italie] ; Eduardo Tolosa [Espagne] ; Werner Poewe [Autriche] ; Erwin Surmann [Allemagne] ; John Whitesides [États-Unis] ; Babak Boroojerdi [Allemagne] ; Kallol Ray Chaudhuri [Royaume-Uni] ; the RECOVER Study Group | Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER) |
000271 (2011) |
Helge Hellriegel [Allemagne] ; Jan Raethjen [Allemagne] ; G. Deuschl [Allemagne] ; Jens Volkmann [Allemagne] | Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study |
000329 (2011) |
S. Wailke [Allemagne] ; J. Herzog [Allemagne] ; K. Witt [Allemagne] ; G. Deuschl [Allemagne] ; J. Volkmann [Allemagne] | Effect of controlled‐release levodopa on the microstructure of sleep in Parkinson’s disease |
000384 (2011) |
Anna Prats París [Espagne] ; Heidi Guerra Saleta [Espagne] ; Maria De La Cruz Crespo Maraver [Espagne] ; Emmanuel Silvestre [États-Unis] ; Maite Garolera Freixa [Espagne] ; Cristina Petit Torrellas [Espagne] ; Silvia Alonso Pont [Espagne] ; Marc Fabra Nadal [Espagne] ; Sheila Alcaine Garcia [Espagne] ; Maria Victoria Perea Bartolomé [Espagne] ; Valentina Ladera Fernández [Espagne] ; Àngels Rusi Ol Bayés [Espagne] | Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease |
000407 (2011) |
Daniela Berg [Allemagne] ; Jana Godau [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Karla Eggert [Allemagne] ; Iiona Csoti [Allemagne] ; Alexander Storch [Allemagne] ; Heiko Huber [Allemagne] ; Monica Morelli-Canelo [Allemagne] ; Maria Stamelou [Allemagne] ; Vincent Ries [Allemagne] ; Martin Wolz [Allemagne] ; Christine Schneider [Allemagne] ; Thérèse Di Paolo [Canada] ; Fabrizio Gasparini [Suisse] ; Sam Hariry [Suisse] ; Marc Vandemeulebroecke [Suisse] ; Walid Abi-Saab [Suisse] ; Katy Cooke [Royaume-Uni] ; Donald Johns [Suisse] ; Baltazar Gomez-Mancilla [Suisse] | AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials |
000411 (2011) |
Kitty K. Wong [Australie] ; Jane E. Alty [Australie] ; Amanda G. Goy [Australie] ; Sanjay Raghav [Australie] ; David C. Reutens [Australie] ; Peter A. Kempster [Australie] | A randomized, double‐blind, placebo‐controlled trial of levetiracetam for dyskinesia in Parkinson's disease |
000520 (2010) |
Endre Pal [Hongrie] ; Ferenc Nagy [Hongrie] ; Zsuzsanna Aschermann [Hongrie] ; Eva Balazs [Hongrie] ; Norbert Kovacs [Hongrie] | The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: A randomized, double‐blind, placebo‐controlled study |
000544 (2010) |
Linda Tickle-Degnen [États-Unis] ; Terry Ellis [États-Unis] ; Marie H. Saint-Hilaire [États-Unis] ; Cathi A. Thomas [États-Unis] ; Robert C. Wagenaar [États-Unis] | Self‐management rehabilitation and health‐related quality of life in Parkinson's disease: A randomized controlled trial |
000549 (2010) |
Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne] | Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study |
000611 (2010) |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study |
000673 (2010) |
E. Ray Dorsey [États-Unis] ; Lisa M. Deuel [États-Unis] ; Tiffini S. Voss [États-Unis] ; Kara Finnigan [États-Unis] ; Benjamin P. George [États-Unis] ; Sheelah Eason [États-Unis] ; David Miller [États-Unis] ; Jason I. Reminick [États-Unis] ; Anna Appler [États-Unis] ; Joyce Polanowicz [États-Unis] ; Lucy Viti [États-Unis] ; Sandy Smith [États-Unis] ; Anthony Joseph [États-Unis] ; Kevin M. Biglan [États-Unis] | Increasing access to specialty care: A pilot, randomized controlled trial of telemedicine for Parkinson's disease |
000769 (2010) |
Pablo Arias [Espagne] ; Jamile Vivas [Espagne] ; Kenneth L. Grieve [Espagne, Royaume-Uni] ; Javier Cudeiro [Espagne] | Controlled trial on the effect of 10 days low‐frequency repetitive transcranial magnetic stimulation (rTMS) on motor signs in Parkinson's disease |
000841 (2010) |
Barry J. Snow [Nouvelle-Zélande] ; Fiona L. Rolfe [Nouvelle-Zélande] ; Michelle M. Lockhart [Nouvelle-Zélande] ; Christopher M. Frampton [Nouvelle-Zélande] ; John D. O'Sullivan [Australie] ; Victor Fung [Australie] ; Robin A. J. Smith [Nouvelle-Zélande] ; Michael P. Murphy [Royaume-Uni] ; Kenneth M. Taylor [Nouvelle-Zélande] | A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease |
000920 (2009) |
Leon Poltawski [Royaume-Uni] ; Hazel Edwards [Royaume-Uni] ; Amy Todd [Royaume-Uni] ; Tim Watson [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Cherry Ann James [Royaume-Uni] | Ultrasound treatment of cutaneous side‐effects of infused apomorphine: A randomized controlled pilot study |
000975 (2009) |
Iracema Leroi [Royaume-Uni] ; Ross Overshott [Royaume-Uni] ; E. Jane Byrne [Royaume-Uni] ; Emily Daniel [Royaume-Uni] ; Alistair Burns [Royaume-Uni] | Randomized controlled trial of memantine in dementia associated with Parkinson's disease |
000B03 (2009) |
Behzad Elahi [Canada] ; Behrad Elahi [Iran] ; Robert Chen [Canada] | Effect of transcranial magnetic stimulation on Parkinson motor function—Systematic review of controlled clinical trials |
000B23 (2009) |
Roberta Zangaglia [Italie] ; Claudio Pacchetti [Italie] ; Chiara Pasotti [Italie] ; Francesca Mancini [Italie] ; Domenico Servello [Italie] ; Elena Sinforiani [Italie] ; Silvano Cristina [Italie] ; Marco Sassi [Italie] ; Giuseppe Nappi [Italie] | Deep brain stimulation and cognitive functions in Parkinson's disease: A three‐year controlled study |